Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors

How to cite:
Wang, Shudong; Midgley, Carol A.; Scareou, Frederic; Grabarek, Joanna B.; Griffiths, Gary; Jackson, Wayne; Kontopidis, George; McClue, Steven J.; McInnes, Campbell; Meades, Christopher; Mezna, Mokdad; Plater, Andy; Stuart, Iain; Thomas, Mark P.; Wood, Gavin; Clarke, Rosemary G.; Blake, David G.; Zheleva, Daniella I.; Lane, David P.; Jackson, Robert C.; Glover, David M. and Fischer, Peter M. (2010). Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors. Journal of Medicinal Chemistry, 53(11) pp. 4367–4378.

For guidance on citations see FAQs.

© 2010 American Chemical Society

Version: Accepted Manuscript

Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1021/jm901913s

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies page.
Supporting Information

Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors

Shudong Wang,† Carol A. Midgley, Frederic Scaërou, Joanna B. Grabarek, Gary Griffiths, Wayne Jackson, George Kontopidis,† Steven J. McClue, Campbell McInnes,† Christopher Meades, Mokdad Mezna, Andy Plater, Iain Stuart, Mark P. Thomas, Gavin Wood, Rosemary G. Clarke, David G. Blake, Daniella I. Zheleva, * David P. Lane, Robert C. Jackson, David M. Glover, and Peter M. Fischer†,*

Cyclacel Limited, 1 James Lindsay Place, Dundee DD1 5JJ, Scotland, UK

Table of Contents

Supporting Figure 1. Kinase inhibitory activity of compound 18 S2
Supporting Figure 2. Activity of compound 18 in tumor models S3
Synthesis and Characterization of Compounds 7h, 11–17, and 19–24 S4
Biopharmaceutical Profiling S7
Rat Pharmacokinetics S7
Cell Viability Assay S7
Murine P388/D1 Leukemia Model S7
NCI-H460 Xenograft S7
X-Ray Crystallography S8
Molecular Modeling S8
Supplementary References S8

† Current addresses. For C.Mcl.: South Carolina College of Pharmacy, CLS 514, 715 Sumter St., University of South Carolina, Columbia, SC 29208, USA. For G.K.: Biochemistry Laboratory, Veterinary School, University of Thessaly, Karditsa 43100, Greece. For S.W. and P.M.F.: School of Pharmacy and Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG7 2RD, UK.

* To whom correspondence should be addressed. For D.I.Z. (Cyclacel): phone, +44-1382-206062; E-mail: dzheleva@cyclacel.com. For P.M.F. (chemistry): phone, +44-115-8466242; E-mail: peter.fischer@nottingham.ac.uk.
Supporting Figure 1. Kinase inhibitory activity of compound 18. The assays were carried out in the presence of 5 µM compound 18 and the ATP concentrations were the $K_M,_{ATP}$ for the individual kinases.
Supporting Figure 2. Activity of compound 18 in tumor models. Murine P388/D1 model (a). Tumor-bearing animals were dosed orally twice daily on days 1–3 and 7–9 with: vehicle control (●), 45 mg/kg/dose 18 (■), or 67 mg/kg/dose 18 (▲). Murine NCI-H460 non-small cell lung cancer xenograft model (b). Starting on day 1 and for 5 days, groups of ten animals were administered orally: vehicle control (●), 75 mg/kg/dose 18 once daily (▲), or 100 mg/kg/dose 18 once daily (■). Standard error means (SEM) are indicated and growth reduction compared to the vehicle control was statistically significant for measurements on days 6 and 9 (*, P < 0.05; **, P < 0.001) as shown.
Synthesis and Characterization of Compounds 7h, 11 – 17, and 19 – 24

1-(4-(4-Aminophenyl)piperazin-1-yl)ethanone (7h). 1-(4-(4-nitrophenyl)piperazin-1-yl)-ethanone 6h was prepared as described: \(^1\) Orange solid. \(^1\)H-NMR (DMSO-\(d_6\)): \(\delta\) 2.15 (s, 3H, CH\(_3\)), 3.26 (dd, 2H, \(J = 5.5\) Hz, CH\(_2\)), 3.30 (dd, 2H, \(J = 5.5\) Hz, CH\(_2\)), 3.66 (dd, 2H, \(J = 5.5\) Hz, CH\(_2\)), 3.80 (dd, 2H, \(J = 5.5\) Hz, CH\(_2\)), 7.20 (d, 1H, \(J = 5.0\) Hz, Ph-H), 7.40 (d, 1H, \(J = 5.0\) Hz, Ph-H), 7.70 (d, 1H, \(J = 5.0\) Hz, Ph-H), 7.72 (s, 1H, Ph-H). Treatment of a solution of 6h in AcOH/EtOH (1:2, v/v) with Fe (3 eq) and heating at 80°C afforded the title compound 7h as a yellow oil in 90% yield. \(^1\)H-NMR (DMSO-\(d_6\)): \(\delta\) 2.07 (s, 3H, CH\(_3\)), 3.08 (m, 4H, CH\(_2\)), 3.55 (m, 2H, CH\(_2\)), 6.22 (d, 1H, \(J = 8.0\) Hz, Ph-H), 6.25 (s, 1H, Ph-H), 6.32 (d, 1H, \(J = 8.0\) Hz, Ph-H), 7.00 (dd, 1H, \(J = 8.0\) Hz, Ph-H).

**N\(^1\)-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]-N\(^4\)-methylbenzene-1,4-diamine (11).** By condensation between enaminone 4a and phenylguanidine 8c. Yellow crystals (68%); mp 155–156°C. Anal. RP-HPLC: \(t_R = 19.9\) min (5–60% MeCN; purity 100%). \(^1\)H-NMR (DMSO-\(d_6\)): \(\delta\) 2.59 (s, 3H, CH\(_3\)), 2.62 (s, 3H, CH\(_3\)), 4.75 (bs, 2H, NH\(_2\)), 6.51 (d, 1H, \(J = 8.5\) Hz, Ph-H), 6.91 (d, 1H, \(J = 4.9\) Hz, Py-H), 7.31 (d, 2H, \(J = 7.8\) Hz, Ph-H), 8.38 (d, 1H, \(J = 5.4\) Hz, Py-H), 9.16 (s, 1H, NH). \(^1\)3C-NMR (DMSO-\(d_6\)): \(\delta\) 15.04, 19.65, 30.92, 107.86, 112.23, 122.09, 129.90, 146.27, 152.31, 158.51, 159.58, 160.76, 166.77. MS (ESI\(^+\)): \(m/z\) 312.42 \([M+H]^+\). Anal. (C\(_{16}\)H\(_{13}\)N\(_3\)S) C, H, N.

**N\(^1\)-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]benzene-1,4-diamine (12).** By condensation between enaminone 4d and phenylguanidine 8d. Yellow crystals (82%); mp 206–208°C. Anal. RP-HPLC: \(t_R = 16.0\) min (5–60% MeCN; purity 100%). \(^1\)H-NMR (DMSO-\(d_6\)): \(\delta\) 2.07 (s, 6H, CH\(_3\)), 3.62 (s, 3H, CH\(_3\)), 3.79 (s, 6H, CH\(_3\)), 7.08 (d, 1H, \(J = 5.0\) Hz, Py-H), 7.18 (s, 2H, Ph-H), 8.51 (d, 1H, \(J = 5.0\) Hz, Ph-H), 9.51 (s, 1H, NH). MS (ESI\(^+\)): \(m/z\) 298.03 \([M+H]^+\). Anal. (C\(_{15}\)H\(_{15}\)N\(_3\)S) C, H, N.

4-(2,4-Dimethylthiazol-5-yl)-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine (13). By condensation between enaminone 4e and phenylguanidine 8e. Yellow solid (76%). Anal. RP-HPLC: \(t_R = 14.1\) min (10–70% MeCN, purity 99%). \(^1\)H-NMR (DMSO-\(d_6\)): \(\delta\) 2.46 (s, 3H, CH\(_3\)), 3.61 (s, 3H, CH\(_3\)), 3.61 (s, 3H, CH\(_3\)), 3.81 (s, 6H, CH\(_3\)), 6.90 (d, 1H, \(J = 5.5\) Hz, Py-H), 7.17 (s, 2H, Ph-H), 8.32 (d, 1H, \(J = 5.5\) Hz, Py-H), 9.28 (s, 1H, NH). MS (ESI\(^+\)) \(m/z\) 388.33 \([M+H]^+\). Anal. (C\(_{18}\)H\(_{20}\)N\(_3\)O\(_3\)) C, H, N.

N,4-Dimethyl-5-(2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yl)thiazol-2-amine (14). By condensation between enaminone 4f and phenylguanidine 8f. Yellow solid (86%). Anal. RP-HPLC: \(t_R = 11.1\) min (10–70% MeCN, purity 99%). \(^1\)H-NMR (DMSO-\(d_6\)): \(\delta\) 1.17 (t, 3H, \(J = 7.5\) Hz, CH\(_3\)), 2.45 (s, 3H, CH\(_3\)), 3.61 (s, 3H, CH\(_3\)), 3.80 (s, 6H, CH\(_3\)), 6.90 (d, 1H, \(J = 6.0\) Hz, Py-H), 7.16 (s, 2H, Ph-H), 8.13 (m, 1H, NH), 8.32 (d, 1H, \(J = 5.5\) Hz, Py-H), 9.27 (s, 1H, NH). MS (ESI\(^+\)) \(m/z\) 402.37 \([M+H]^+\). Anal. (C\(_{19}\)H\(_{23}\)N\(_3\)O\(_3\)) C, H, N.

S4
N-(4-(4-(2-(Ethylamino)-4-methylthiazol-5-yl)pyrimidin-2-ylamino)phenyl)acetamide (16). By condensation between enamino 4d and phenylguanidine 8f. Pale solid (57%); mp 210–212 °C. Anal. RP-HPLC: tR = 12.3 min (5–60% MeCN; purity 92%). 1H-NMR (DMSO-d6): δ 1.28 (t, 3H, J = 7.0 Hz, CH3), 1.99 (s, 3H, CH3), 2.52 (s, 3H, CH3), 3.36 (q, 2H, J = 7.0, 14.5 Hz, CH2), 4.31 (s, 2H, CH2) 6.9 (d, 1H, J = 5.5 Hz, Py-H), 7.22 (d, 2H, J = 8.5 Hz, Ph-H), 7.66 (d, 2H, J = 9.0 Hz, Ph-H), and 8.25 (d, 1H, J = 5.5Hz, Py-H). 13C-NMR (DMSO-d6): δ 14.95, 19.33, 23.27, 40.41, 107.34, 118.30, 119.25, 128.23, 132.80, 140.06, 152.85, 158.24, 159.22, 160.10, 168.92, 169.64. HRMS (ESI†): m/z 383.16491 [M+H]+. Anal. (C19H22N6OS) C, H, N.

4-(2,4-Dimethylthiazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine (17). By condensation between enamino 4a and phenylguanidine 8g. Pale solid (74%); mp 117–120 °C. 1H-NMR (DMSO-d6): δ 2.61 (s, 3H, CH3), 2.63 (s, 3H, CH3), 3.04 (m, 4H, CH2), 3.73 (m, 4H, CH2), 6.91 (d, 1H, J = 9.5 Hz, Ph-H), 6.99 (d, 2H, J = 5.5 Hz, Py-H), 7.61 (d, 2H, J = 9.5 Hz, Ph-H), 8.44 (d, 1H, J = 5.0 Hz, Py-H). 13C-NMR (DMSO-d6): δ 18.56, 19.68, 49.94, 66.88, 108.39, 116.25, 120.98, 121.01, 133.36, 146.95, 152.47, 159.67, 159.68, 160.50, 166.92. MS (ESI†): m/z 368.00 [M+H]+. Anal. (C19H22N6OS) C, H, N.

N4-Dimethyl-5-(2-(4-morpholinophenyl)pyrimidin-4-yl)thiazol-2-amine (19). By condensation between enamino 4c and phenylguanidine 8g. Pale solid (81%); mp 286–289 °C. Anal. RP-HPLC: tR = 10.8 min (0–60% MeCN; purity 99%). 1H-NMR (DMSO-d6): δ 2.46 (s, 3H, CH3), 2.85 (m, 3H, CH3), 3.03 (m, 4H, CH2), 3.73 (m, 4H, CH2), 6.81 (d, 1H, J = 5.5 Hz, Py-H), 6.87 (d, 2H, J = 8.5 Hz, Ph-H), 7.61 (d, 2H, J = 8.5 Hz, Ph-H), 8.00 (bs, 1H, NH), 8.26 (d, 1H, J = 5.5 Hz, Py-H), 9.17 (bs, 1H, NH). 13C-NMR (DMSO-d6): δ 19.32, 31.44, 50.03, 66.89, 106.86, 116.27, 120.74, 120.78, 133.83, 146.66, 152.69, 158.27, 159.28, 160.30, 169.88. MS (ESI†): m/z 383.13 [M+H]+. Anal. (C19H22N6OS) C, H, N.

N-Ethyl-4-methyl-5-(2-(4-morpholinophenyl)pyrimidin-4-yl)thiazol-2-amine (20). By condensation between enamino 4b and phenylguanidine 8h. Light yellow solid (58%); mp 267–269 °C. Anal. RP-HPLC: tR = 7.21 min (10–70% MeCN; purity 100%). 1H-NMR (DMSO-d6): δ 1.16 (t, 3H, J = 3.5 Hz, CH3), 2.45 (s, 3H, CH3), 3.02 (m, 4H, CH2), 3.28 (m, 2H, CH2), 3.73 (m, 4H, CH2), 6.81 (d, 1H, J = 6.0 Hz, Py-H), 6.87 (d, 2H, J = 8.5 Hz, Ph-H), 7.61 (d, 2H, J = 8.5 Hz, Ph-H), 8.05 (m, 1H, NH), 8.26 (d, 1H, J = 6.0 Hz, Py-H), 9.17 (bs, 1H, NH). 13C-NMR (DMSO-d6): δ 15.00, 19.33, 50.04, 66.89, 106.89, 116.26, 118.40, 120.73, 133.84, 146.64, 152.61, 158.22, 159.28, 160.29, 164.81. MS (ESI†): m/z 396.98 [M+H]+. Anal. (C20H24N6OS) C, H, N.

1-(4-(4-(4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone (21). By condensation between enamino 4b and phenylguanidine 8h. Light yellow solid (58%); mp 267–269 °C. Anal. RP-HPLC: tR = 7.21 min (10–70% MeCN; purity 100%). 1H-NMR (DMSO-d6): δ 2.42 (s, 3H, CH3), 3.00 (m, 2H, CH2), 3.07 (m, 2H, CH2), 3.29 (s, 3H, CH3), 3.58 (m, 4H, CH2), 6.81 (d, 1H, J = 5.5 Hz, Py-H), 6.89 (d, 2H, J = 9.0 Hz, Ph-H), 7.46 (s, 2H, NH2), 7.62 (d, 2H, J = 8.0 Hz, Ph-H), 8.26 (d, 1H, J = 5.5 Hz, Py-H), 9.19 (bs, 1H, NH). 13C-NMR (DMSO-d6): δ 19.10, 21.90, 41.49, 46.31, 49.97, 50.40, 107.01, 117.19, 118.90, 120.69, 134.11, 146.38, 152.43, 158.26, 159.33, 160.38, 168.94, 169.42. MS (ESI†): m/z 410.52 [M+H]+. Anal. (C20H23N5O2S) C, H, N.

1-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone (22). By condensation between enamino 4c and phenylguanidine 8h. Yellow solid (69%); mp 230–231 °C. Anal. RP-HPLC: tR = 8.8 min (10–70% MeCN ;purity 97%). 1H-NMR (DMSO-d6): δ 2.85 (s, 3H, CH3), 2.99 (m, 2H, CH2), 3.07 (m, 2H, CH2), 3.16 (s, 3H, CH3), 3.27 (s, 3H, CH3), 3.57 (m, 4H, CH2), 6.82 (d, 1H, J =
6.0 Hz, Py-H), 6.89 (d, 2H, J = 9.0 Hz, Ph-H), 7.61 (d, 2H, J = 9.0 Hz, Ph-H), 8.26 (d, 1H, J = 5.5 Hz, Py-H), 9.18 (s, 1H, NH). \(^{13}\)C-NMR (DMSO-d\(_6\)): \(\delta\) 14.79, 21.46, 21.91, 41.50, 46.32, 49.29, 60.46, 117.26, 120.72, 122.02, 134.11, 145.35, 146.41, 152.73, 160.28, 164.55, 165.93, 168.94, 171.05. MS (ESI\(^+\)): \(m/z\) 424.07 [M+H]\(^+\). Anal. (C\(_{21}\)H\(_{25}\)N\(_7\)O\(_2\)) C, H, N.

1-(4-(4-(4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone (23). By condensation between enaminone 4a and phenylguanidine 8h. Yellow solid (67%); mp 151-153 °C. Anal. RP-HPLC: \(t_R = 12.1\ \text{min}\) (10–70% MeCN; purity 100%). \(^1\)H-NMR (DMSO-d\(_6\)) : \(\delta\) 2.61 (s, 3H, CH\(_3\)), 2.64 (s, 3H, CH\(_3\)), 3.01 (t, 2H, J = 5.5 Hz, CH\(_2\)), 3.07 (t, 2H, J = 5.0 Hz, CH\(_2\)), 3.34 (s, 3H, CH\(_3\)), 3.57 (m, 4H, CH\(_2\)), 6.93 (d, 2H, J = 8.5 Hz, Ph-H), 6.99 (d, 1H, J = 5.0 Hz, Py-H), 7.62 (d, 2H, J = 9.5 Hz, Ph-H), 8.44 (d, 1H, J = 5.5 Hz, Py-H), 9.43 (s, 1H, NH). \(^{13}\)C-NMR (DMSO-d\(_6\)) : \(\delta\) 18.57, 19.68, 21.90, 41.46, 46.30, 49.88, 50.31, 108.43, 117.18, 120.95, 131.61, 133.64, 146.69, 158.56, 159.72, 160.48, 166.94, 168.93. MS (ESI\(^+\)) : \(m/z\) 409.31 [M+H]\(^+\). Anal. (C\(_{21}\)H\(_{24}\)N\(_6\)O\(_2\)) C, H, N.

4-(2,4-Dimethylthiazol-5-yl)-N-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrimidin-2-amine (24). By condensation between enaminone 4a and phenylguanidine 8i. Yellow solid (62%). \(^1\)H-NMR (CDCl\(_3\)) : \(\delta\) 2.69 (s, 3H, CH\(_3\)), 2.71 (s, 3H, CH\(_3\)), 2.84 (s, 3H, CH\(_3\)), 3.26 (t, 4H, J = 5.1 Hz, CH\(_2\)), 3.41 (t, 4H, J = 5.1 Hz, CH\(_2\)), 6.91 (d, 1H, J = 5.1 Hz, Py-H), 6.98 (d, 2H, J = 8.8 Hz, Py-H), 7.10 (bs, 1H, NH), 7.56 (d, 2H, J = 8.8 Hz, Ph-H), 8.38 (d, 1H, J = 5.1 Hz, Ph-H). MS (ESI\(^+\)) : \(m/z\) 446.00 [M+H]\(^+\). Anal. (C\(_{20}\)H\(_{24}\)N\(_6\)O\(_2\)S\(_2\)) C, H, N.
Biopharmaceutical Profiling. Test compound partitioning between octanol and aqueous buffer was carried out using the shake-flask method. Compound $pK_a$ values were determined using a pH-metric titration method (GLpKa; Sirius). Aqueous solubility was assessed by turbidimetric measurements. Apparent permeability coefficients were measured using a Caco-2 cell layer assay. In vitro phase-I liver metabolism was assessed by disappearance of parent compound (LC-MS quantitation) from a preparation of rat liver microsomes. Rat plasma protein binding was determined in an equilibrium dialysis assay. hERG inhibition was assessed using automated patch clamp electrophysiology measurement in CHO-hERG cells.

Rat Pharmacokinetics. The PK parameters for test compounds were determined in male Wistar rats. For each compound, 3 rats were dosed either by intravenous bolus injection or by oral gavage. Dose volume was 10 mL/kg for oral gavage administration and 12 mL/kg for intravenous administration (1mL/min). Three serum samples were collected from each rat by jugular vein cannulation at 0, 5, 15, and 30 min, 1, 2, 4, and 6 h following i.v. dosing; and at 0, 0.5, 1, 2, 4, 6, 8, and 24 h after p.o. dosing. All blood samples were centrifuged immediately following collection. The plasma was harvested and stored at −20 °C until analysis. The samples were analyzed by LC-MS/MS methods. The PK parameters were derived by noncompartmental methods using WinNonlin 5.2 software program (Pharsight). The oral bioavailability (% F) was calculated by taking the ratio of dose-normalized AUC values from oral versus i.v. dosing.

Cell Viability Assay. Inhibition of cell growth was measured by a standard MTT (thiazolyl blue; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay using a panel of tumor cell lines. Briefly: cells were seeded (2,500–5,000 cells/well) in 96-well plates and allowed to attach for ~ 24 h. Cells were incubated with test compounds for 96 h in DMEM medium containing 10% fetal bovine serum. Cells were treated with a range of compound concentrations in triplicate to generate dose-response curves. The compound concentration required to inhibit 50% of cell growth (IC$_{50}$) was determined using nonlinear regression analysis.

Murine P388/D1 Leukemia Model. Female Balb/c × DBA/2J F1 mice were implanted intraperitoneally with $2.1 \times 10^5$ P388/D1 leukemia cells on day 0. Starting on day 1 the animals were administered compound 18 by oral gavage at the indicated doses (0.1 mL / 10 g body weight) twice a day on days 1–3 and 7–9. The effectiveness of treatment was assessed by comparison of the median post-inoculation lifespan (ILS) of each group of treated mice with that of the vehicle control group. The ratio of ILS values for the treated versus the control groups was expressed as a percentage value (% ILS) and used as an indicator of relative efficacy.

NCI-H460 Xenograft. Human NCI-H460 non-small cell lung tumor cells were harvested from sub-confluent cultures grown in vitro and the number of viable cells was determined. Cells were then resuspended in sterile PBS at a concentration of ca. $7 \times 10^7$ cells/mL. Nude (athymic) mice were injected subcutaneously in the right flank with approximately $7 \times 10^6$ cells. When measurable tumors had established (80-100 mm$^3$), animals were assigned into the treatment and the control groups with 10 mice per group. Tumor size was measured at least twice weekly. Animals were terminated at any time during the study if the tumor size became excessive or any adverse effects were noted. The treatments were administrated orally, by gavage, daily, starting on day 1, and continuing for 5 days. In the control group, animals were treated with the vehicle orally, by gavage, once a day starting on day 1, and continuing for 5 days. The tumor dimensions measured over the period of the study were recorded. Calculations of relative tumor volumes and plots of mean tumor growth curves were
performed. The relative tumor volume data from each group were compared using a one-way analysis of variance (ANOVA) and statistical significance was determined using a Dunnett’s t-test.

**X-Ray Crystallography.** Protein production and crystallography methods have been described previously. Data were collected at the Grenoble (France) synchrotron facilities using an ADSC Quantum4 CCD detector. Data processing was carried out using the programs MOSFLM and SCALA from the CCP4 program suite. The 18-CDK2-cyclin A complex structure was solved by molecular replacement using MOLREP and PDB entry 1OKV as the search model. ARP/wARP was used for initial density interpretation and the addition of water molecules. REFMAC was used for structural refinement. A number of rounds of refinement and model building with the program Quanta (Accelrys, San Diego, USA) were carried out. Coordinates of the 18–CDK2-cyclin A complex structure have been deposited with the RCSB under accession code 2UUE.

**Molecular Modeling.** The structure coordinates of aurora A were obtained from the RCSB (accession code 1OL5). Inhibitors were docked into the ATP site using the Affinity program (Accelrys, San Diego, CA). The binding site was defined as an 8 Å radius from the centre of a ligand binding mode. The molecular docking routine adopted, which incorporated a full molecular mechanics approach, allows for flexibility both in the ligand and in the side chains and backbone of the receptor (the positions of the Cα atoms were fixed during the simulation). The calculation was performed using the CVFF force field in a two-step process using an implicitly derived solvation model and geometric hydrogen bond restraints. For the initial phase of the calculation, the inhibitor was minimized into the ATP cleft, using a simple non-bonded method where the Coulombic and van der Waals terms were scaled to zero and 0.1, respectively. The subsequent refinement phase involved conformational sampling using molecular dynamics calculated over 5 ps in 100 fs stages, where the temperature was scaled from 500 K to 300 K. The calculation was completed by a final minimization over 1,000 steps using the Polak-Ribiere Conjugate Gradient method. The docked structures were ranked energetically (using the in-house developed programs Calsor and Calsorcont, values reported in kcal/mol) and by consistency of the non-bonded contacts with the CDK binding pose and known kinase interactions, in order to determine the most representative binding mode.

**Supplementary References**


